2024
Prediagnostic Plasma Nutrimetabolomics and Prostate Cancer Risk: A Nested Case–Control Analysis Within the EPIC Study
Almanza-Aguilera E, Martínez-Huélamo M, López-Hernández Y, Guiñón-Fort D, Guadall A, Cruz M, Perez-Cornago A, Rostgaard-Hansen A, Tjønneland A, Dahm C, Katzke V, Schulze M, Masala G, Agnoli C, Tumino R, Ricceri F, Lasheras C, Crous-Bou M, Sánchez M, Aizpurua-Atxega A, Guevara M, Tsilidis K, Chatziioannou A, Weiderpass E, Travis R, Wishart D, Andrés-Lacueva C, Zamora-Ros R. Prediagnostic Plasma Nutrimetabolomics and Prostate Cancer Risk: A Nested Case–Control Analysis Within the EPIC Study. Cancers 2024, 16: 4116. PMID: 39682302, PMCID: PMC11639937, DOI: 10.3390/cancers16234116.Peer-Reviewed Original ResearchProstate cancer riskProstate cancerPCa riskBiomarkers of food intakeMultivariate conditional logistic regression analysisNested Case-Control AnalysisAdvanced PCa riskFatal prostate cancerCancer and NutritionConditional logistic regression analysisOverall PCa riskEuropean Prospective InvestigationMetabolite concentrationsCase-control analysisCase-control pairsLogistic regression analysisClinically relevant tumor subtypesMetabolomics approachTumor subtypesProspective InvestigationClinical subtypesCancer riskFood intakeMetabolic alterationsEPIC studyPerturbations in the blood metabolome up to a decade before prostate cancer diagnosis in 4387 matched case–control sets from the European Prospective Investigation into Cancer and Nutrition
Grenville Z, Noor U, Rinaldi S, Gunter M, Ferrari P, Agnoli C, Amiano P, Catalano A, Chirlaque M, Christakoudi S, Guevara M, Johansson M, Kaaks R, Katzke V, Masala G, Olsen A, Papier K, Sánchez M, Schulze M, Tjønneland A, Tong T, Tumino R, Weiderpass E, Zamora‐Ros R, Key T, Smith‐Byrne K, Schmidt J, Travis R. Perturbations in the blood metabolome up to a decade before prostate cancer diagnosis in 4387 matched case–control sets from the European Prospective Investigation into Cancer and Nutrition. International Journal Of Cancer 2024, 156: 943-952. PMID: 39378119, PMCID: PMC11701393, DOI: 10.1002/ijc.35208.Peer-Reviewed Original ResearchConceptsAssociated with advanced prostate cancerAdvanced prostate cancerProstate cancerEuropean Prospective InvestigationMetabolite patternsAssociated with prostate cancer deathMultivariable-adjusted conditional logistic regressionProspective InvestigationPresence of prostate cancerHigh-grade prostate cancerProstate cancer overallProstate cancer riskProstate cancer deathAdvanced-stage diseaseCancer and NutritionFollow-up timeYear of blood collectionProstate cancer diagnosisMetabolite profile changesCase-control pairsConditional logistic regressionCase-control settingBlood metabolomeCancer overallFollow-upFine Particulate Matter, Noise Pollution, and Greenspace and Prostate Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Cohort.
Thomas A, Rhee J, Fisher J, Horner M, Jones R. Fine Particulate Matter, Noise Pollution, and Greenspace and Prostate Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Cohort. Cancer Epidemiology Biomarkers & Prevention 2024, 33: 857-860. PMID: 38497801, PMCID: PMC11147690, DOI: 10.1158/1055-9965.epi-23-1413.Peer-Reviewed Original ResearchProstate cancer riskAssociated with prostate cancer riskCancer riskNoise exposureMale participantsArea Deprivation IndexFamily history of prostate cancerFine particulate matterTrial cohortEnrollment addressHistory of prostate cancerDeprivation indexPotential risk factorsGreenspace exposureEstimate associationsMultipollutant modelsCox regression modelsFamily historyProstate cancerSingle-pollutantCases of prostate cancerProspective ProstateRisk factorsU.S. studiesIncident prostate cancer risk
2023
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
Wang A, Shen J, Rodriguez A, Saunders E, Chen F, Janivara R, Darst B, Sheng X, Xu Y, Chou A, Benlloch S, Dadaev T, Brook M, Plym A, Sahimi A, Hoffman T, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X, Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury P, Schleutker J, Tammela T, Sipeky C, Auvinen A, Giles G, Southey M, MacInnis R, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch C, Cho K, Mcmahon B, Neal D, Donovan J, Hamdy F, Martin R, Nordestgaard B, Nielsen S, Weischer M, Bojesen S, Røder A, Stroomberg H, Batra J, Chambers S, Horvath L, Clements J, Tilly W, Risbridger G, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning A, Ghoussaini M, Travis R, Key T, Riboli E, Park J, Sellers T, Lin H, Albanes D, Weinstein S, Cook M, Mucci L, Giovannucci E, Lindstrom S, Kraft P, Hunter D, Penney K, Turman C, Tangen C, Goodman P, Thompson I, Hamilton R, Fleshner N, Finelli A, Parent M, Stanford J, Ostrander E, Koutros S, Beane Freeman L, Stampfer M, Wolk A, Håkansson N, Andriole G, Hoover R, Machiela M, Sørensen K, Borre M, Blot W, Zheng W, Yeboah E, Mensah J, Lu Y, Zhang H, Feng N, Mao X, Wu Y, Zhao S, Sun Z, Thibodeau S, McDonnell S, Schaid D, West C, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel A, Drake B, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou Y, John E, Grindedal E, Maehle L, Khaw K, Ingles S, Stern M, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein B, Kerns S, Ostrer H, Teixeira M, Paulo P, Brandão A, Watya S, Lubwama A, Bensen J, Butler E, Mohler J, Taylor J, Kogevinas M, Dierssen-Sotos T, Castaño-Vinyals G, Cannon-Albright L, Teerlink C, Huff C, Pilie P, Yu Y, Bohlender R, Gu J, Strom S, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach R, Brenner H, Chen X, Holleczek B, Schöttker B, Klein E, Hsing A, Kittles R, Murphy A, Logothetis C, Kim J, Neuhausen S, Steele L, Ding Y, Isaacs W, Nemesure B, Hennis A, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo S, Newcomb L, Lin D, Fowke J, Neslund-Dudas C, Rybicki B, Gamulin M, Lessel D, Kulis T, Usmani N, Abraham A, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castelao J, Martinez M, Larkin S, Townsend P, Aukim-Hastie C, Bush W, Aldrich M, Crawford D, Srivastava S, Cullen J, Petrovics G, Casey G, Wang Y, Tettey Y, Lachance J, Tang W, Biritwum R, Adjei A, Tay E, Truelove A, Niwa S, Yamoah K, Govindasami K, Chokkalingam A, Keaton J, Hellwege J, Clark P, Jalloh M, Gueye S, Niang L, Ogunbiyi O, Shittu O, Amodu O, Adebiyi A, Aisuodionoe-Shadrach O, Ajibola H, Jamda M, Oluwole O, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Diop H, Gundell S, Roobol M, Jenster G, van Schaik R, Hu J, Sanderson M, Kachuri L, Varma R, McKean-Cowdin R, Torres M, Preuss M, Loos R, Zawistowski M, Zöllner S, Lu Z, Van Den Eeden S, Easton D, Ambs S, Edwards T, Mägi R, Rebbeck T, Fritsche L, Chanock S, Berndt S, Wiklund F, Nakagawa H, Witte J, Gaziano J, Justice A, Mancuso N, Terao C, Eeles R, Kote-Jarai Z, Madduri R, Conti D, Haiman C. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nature Genetics 2023, 55: 2065-2074. PMID: 37945903, PMCID: PMC10841479, DOI: 10.1038/s41588-023-01534-4.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesMulti-ancestry genome-wide association studyNovel risk variantsRisk variantsAssociation studiesProstate cancer genome-wide association studiesCancer genome-wide association studyGenome-wide discoveryProstate cancer susceptibility lociGenetic risk scoreCancer susceptibility lociEuropean ancestry menGenetic studiesSusceptibility lociNon-aggressive diseaseEffective risk stratificationAfrican ancestry menProstate cancer riskAncestry groupsProstate cancer casesRisk stratificationAfrican ancestryProstate cancerCancer casesCancer riskIdentification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects
Zhong H, Zhu J, Liu S, Ghoneim D, Surendran P, Liu T, Fahle S, Butterworth A, Alam A, Deng H, Yu H, Wu C, Wu L. Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects. Human Molecular Genetics 2023, 32: 3181-3193. PMID: 37622920, PMCID: PMC10630250, DOI: 10.1093/hmg/ddad139.Peer-Reviewed Original ResearchConceptsPCa riskProstate cancerHuge public health burdenEtiology of PCaBlood protein biomarkersConventional epidemiologic studiesProstate cancer riskPublic health burdenConventional observational studiesCancer Genome AtlasPCa patientsHealth burdenProtein biomarker candidatesObservational studyEpidemiologic studiesCancer riskTherapeutic strategiesCancer-related pathwaysSignificant associationBiomarker candidatesGenome AtlasProtein levelsDrug repurposingRiskPositive associationPatient experiences with tissue‐based genomic testing during active surveillance for prostate cancer
Leapman M, Sutherland R, Gross C, Ma X, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman‐Green D. Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer. BJUI Compass 2023, 5: 142-149. PMID: 38179031, PMCID: PMC10764160, DOI: 10.1002/bco2.277.Peer-Reviewed Original ResearchActive surveillanceProstate cancerGene expression testGenomic testingCancer riskPatient experienceGrade group 2 prostate cancerGleason Grade Group 1Risk prostate cancerGrade group 1Prostate cancer riskProstate cancer managementProstate cancer aggressivenessHereditary cancer riskGermline genetic testsTissue-based testsGenomic test resultsConclusions PatientsInitial biopsyPhysician recommendationPatient knowledgePatient counsellingConventional content analysisCancer managementExpression testMelatonin and Prostate Cancer: Anti-tumor Roles and Therapeutic Application
Megerian M, Kim J, Badreddine J, Hong S, Ponsky L, Shin J, Ghayda R. Melatonin and Prostate Cancer: Anti-tumor Roles and Therapeutic Application. Aging And Disease 2023, 14: 840-857. PMID: 37191417, PMCID: PMC10187692, DOI: 10.14336/ad.2022.1010.Peer-Reviewed Original ResearchProstate cancerModel of prostate cancerTreatment of prostate cancerProstate cancer riskInhibited tumor growthEfficacy of supplementationNeuroendocrine differentiationAndrogen signalingModulate metabolic activityMelatonin therapyTumor growthCancer riskClinical trialsProstateAssociated with exogenous factorsCancerCell cycle progressionEpidemiological evidenceSecretory activityEndogenous indoleaminePineal secretory activityCell statusPoor sleepCycle progressionCircadian rhythmPatient experiences with tissue-based genomic testing during active surveillance for prostate cancer.
Leapman M, Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D. Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer. Journal Of Clinical Oncology 2023, 41: 333-333. DOI: 10.1200/jco.2023.41.6_suppl.333.Peer-Reviewed Original ResearchActive surveillanceProstate cancerGene expression testGenomic testingCancer riskPatient experienceGleason Grade Group 1Risk prostate cancerGrade group 1Routine clinical careProstate cancer riskGroup 2 tumorsProstate cancer managementProstate cancer aggressivenessHereditary cancer riskGermline genetic testsTissue-based testsRace/ethnicityInitial biopsyPatient knowledgeMean agePatient counselingCancer managementClinical careExpression testGenetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention
Seibert T, Garraway I, Plym A, Mahal B, Giri V, Jacobs M, Cheng H, Loeb S, Helfand B, Eeles R, Morgan T. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. European Urology 2023, 83: 241-248. PMID: 36609003, DOI: 10.1016/j.eururo.2022.12.021.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTimes higher riskGenetic risk scoreHigh genetic risk scoreLethal prostate cancerProstate cancerHigh genetic riskHigh riskRare pathogenic mutationsHealthy lifestyleEarly detectionPCa riskRisk predictionHigh-grade prostate cancerGenetic riskAggressive prostate cancerProstate cancer riskGenetic risk assessmentDNA damage repair genesGenetic risk predictionPCa mortalityAggressive diseaseLeading causeFamily historyCancer riskElevated riskProstate cancer risk, screening and management in patients with germline BRCA1/2 mutations
Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman M, Gore J, Paradysz A, Tilki D, Merseburger A, Morgan T, Briganti A, Palapattu G, Shariat S. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. Nature Reviews Urology 2023, 20: 205-216. PMID: 36600087, DOI: 10.1038/s41585-022-00680-4.Peer-Reviewed Original ResearchConceptsProstate cancer riskBRCA1/2 mutation carriersMagnetic resonance imagingProstate cancerMutation carriersCancer riskProspective studyBRCA2 mutationsProstate cancer-specific mortalityProstate specific antigen measurementsCancer-specific mortalityProstate cancer incidenceAggressive clinical behaviorProstate cancer screeningRisk stratification strategiesLong-term resultsSignificant prostate cancerOptimal screening strategyGermline BRCA1/2 mutationsOptimal screening protocolProstate magnetic resonance imagingQuality of lifeBRCA2 tumor suppressor genesOverall survivalDisease characteristics
2022
Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations
Chen F, Darst BF, Madduri RK, Rodriguez AA, Sheng X, Rentsch CT, Andrews C, Tang W, Kibel AS, Plym A, Cho K, Jalloh M, Gueye SM, Niang L, Ogunbiyi OJ, Popoola O, Adebiyi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Mensah JE, Adjei AA, Diop H, Lachance J, Rebbeck TR, Ambs S, Gaziano JM, Justice AC, Conti DV, Haiman CA. Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations. ELife 2022, 11: e78304. PMID: 35801699, PMCID: PMC9322982, DOI: 10.7554/elife.78304.Peer-Reviewed Original ResearchConceptsProstate cancer riskPolygenic risk scoresProstate cancerCancer riskOdds ratioMillion Veteran ProgramRisk scoreRisk stratification toolAge-specific absolute risksAfrican ancestry menCancer odds ratiosVeterans Health AdministrationCase-control studyNonaggressive prostate cancerProstate Cancer FoundationAge-specific riskAssociation of PRSPRS categoriesRisk-stratified screeningVeteran ProgramNational Cancer InstituteEuropean ancestry menStratification toolAbsolute riskEffect modification
2020
Exploring African American males' attitudes towards genetic testing for prostate cancer risk.
Leader A, Fortune T, Weddington P, Crumpler N, Giri V. Exploring African American males' attitudes towards genetic testing for prostate cancer risk. Journal Of Clinical Oncology 2020, 38: e13552-e13552. DOI: 10.1200/jco.2020.38.15_suppl.e13552.Peer-Reviewed Original ResearchFamily historyGenetic testingAA malesAA menHigher prostate cancer incidencePrimary care visitsProstate cancer incidenceGenetic counselingImportant risk factorProstate cancer riskHealth history informationFocus groupsFamily health historyCare visitsMean ageCancer incidenceRisk factorsCancer riskMortality rateHealth historyLow-resource neighborhoodsCare limitationsInformed consentMost menAfrican American malesHereditary Prostate Cancer
Giri V, Beebe-Dimmer J, Cooney K. Hereditary Prostate Cancer. 2020, 283-292. DOI: 10.1201/9781351187435-33.Peer-Reviewed Original ResearchHereditary prostate cancerProstate cancerCancer syndromesGenetic testing guidelinesMetastatic prostate cancerProstate cancer riskOvarian cancer syndromeHereditary cancer syndromesPrecision oncology studyClinical featuresLynch syndromeFatal cancerCancer riskGenetic predispositionHereditary breastCancerGenetic testingFamilial clusteringTesting guidelinesSyndromeGermline geneticsOncology studiesCancer susceptibilityGermline variationClinical application
2019
Introduction to the 2019 Philadelphia Prostate Cancer Consensus Program: 'Implementation of Genetic Testing for Inherited Prostate Cancer'.
Gomella L, Knudsen K, Giri V. Introduction to the 2019 Philadelphia Prostate Cancer Consensus Program: 'Implementation of Genetic Testing for Inherited Prostate Cancer'. Canadian Journal Of Urology 2019, 26: 1-4. PMID: 31629412.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInherited prostate cancerGenetic testingProstate cancerFirst International Consensus ConferenceKimmel Cancer CenterProstate cancer riskInternational Consensus ConferenceCancer ConsensusCancer CenterThomas Jefferson UniversityCancer riskConsensus meetingConsensus conferenceCancerFollowTesting
2018
Prostate cancer risk factors in black and white men in the NIH-AARP Diet and Health Study
Layne TM, Graubard BI, Ma X, Mayne ST, Albanes D. Prostate cancer risk factors in black and white men in the NIH-AARP Diet and Health Study. Prostate Cancer And Prostatic Diseases 2018, 22: 91-100. PMID: 30108373, PMCID: PMC6676904, DOI: 10.1038/s41391-018-0070-9.Peer-Reviewed Original ResearchConceptsProstate cancer riskHazard ratioWhite menAdvanced diseaseBlack raceRisk factorsCancer riskHealth StudyRisk associationDietary vitamin D intakeProstate cancer risk factorsProportional hazards regression modelsBlack menNon-Hispanic white menPositive risk associationVitamin D intakeHistory of diabetesNIH-AARP DietCancer risk factorsProstate cancer screeningHazards regression modelsConfidence intervalsHealth-related factorsCancer risk associationsRace-specific associationsThe Frequency of CHEK2 variant p.Ile157Thr in Men with Prostate Cancer: Towards Expanded Genetic Testing
Agubokwu N, Giri V. The Frequency of CHEK2 variant p.Ile157Thr in Men with Prostate Cancer: Towards Expanded Genetic Testing. The FASEB Journal 2018, 32: 532.9-532.9. DOI: 10.1096/fasebj.2018.32.1_supplement.532.9.Peer-Reviewed Original ResearchComparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy.
Leapman M, Nguyen H, Cowan J, Xue L, Stohr B, Simko J, Cooperberg M, Carroll P. Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 118-118. DOI: 10.1200/jco.2018.36.6_suppl.118.Peer-Reviewed Original ResearchPCa-specific mortalityRadical prostatectomyBiochemical recurrenceCCP scoreIHC panelCell cycle progression scoreExpression statusERG expressionCox proportional hazards regressionRisk of BCRPositive ERG expressionProportional hazards regressionProstate cancer riskPrediction of outcomeHigh Ki67Median ageIndependent predictorsPathologic characteristicsHazards regressionPrognostic utilityIHC statusInstitutional databaseLocalized PCaC-indexImmunohistochemistry panel
2017
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal Of Clinical Oncology 2017, 36: jco.2017.74.117. PMID: 29236593, PMCID: PMC6075860, DOI: 10.1200/jco.2017.74.1173.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProstate cancerGenetic testingMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerAggressive prostate cancerProstate cancer riskGenetic counselingMultidisciplinary consensus statementDNA mismatch repair genesExpert consensus conferenceFamilial prostate cancerHereditary prostate cancerClinical genetic testingMismatch repair genesMetastatic settingPCa managementLynch syndromeOvarian cancerBRCA2 mutationsConsensus statementFamily historyCancer riskHeterogeneous diseaseConsensus conferenceComprehensive genetic evaluationSerum 25‐hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men
Layne TM, Weinstein SJ, Graubard BI, Ma X, Mayne ST, Albanes D. Serum 25‐hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men. Cancer 2017, 123: 2698-2704. PMID: 28369777, PMCID: PMC5498231, DOI: 10.1002/cncr.30634.Peer-Reviewed Original ResearchConceptsProstate cancer riskD binding proteinVitamin D statusCancer riskD statusOdds ratioProstate cancerLow vitamin D statusSerum DBPOvarian Cancer Screening TrialDecreased prostate cancer riskOverall prostate cancerCancer Screening TrialBlack menProstate cancer screeningApparent inverse associationConfidence intervalsVitamin D binding proteinConditional logistic regressionProstate cancer casesNonaggressive diseaseCohort entryCancer screeningBlood drawInverse association
2016
Familial prostate cancer
Giri V, Beebe-Dimmer J. Familial prostate cancer. Seminars In Oncology 2016, 43: 560-565. PMID: 27899188, PMCID: PMC6986340, DOI: 10.1053/j.seminoncol.2016.08.001.Peer-Reviewed Original ResearchConceptsFamilial prostate cancerProstate cancer riskProstate cancerHereditary prostate cancerBRCA2 mutationsFamily historyCancer riskNational Comprehensive Cancer Network guidelinesGenetic testingProstate cancer screeningFamily cancer historyProstate cancer patientsEarly-onset diseasePositive family historyFirst-degree relativesClustering of casesNetwork guidelinesColorectal cancerCancer historyCancer patientsCancer screeningCommon tumorsRisk factorsSurrogate markerOvarian cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply